TrialReader


Perioral Rejuvenation and Upper Lip Enhancement

NCT03273543 — Not applicable, Completed, 20 participants, DeNova Research

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

Premaxillary Injection for Perioral Rejuvenation and Upper Lip Enhancement

RegistryNCT03273543
StatusCompleted
PhaseNot applicable
Study typeInterventional; non randomized, parallel, masking: none, treatment
Enrollment20 (Actual)
SponsorDeNova Research (Other)
ConditionsPerioral Rejuvenation, Upper Lip Projection
InterventionsRestylane® Defyne (Device)
Datesstart 2017-11-20, primary completion 2018-07-03, completion 2018-07-03, first posted 2017-09-06, last updated 2020-10-08
Locations1 site in United States

Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Perioral Rejuvenation All trials for Upper Lip Projection All trials of Restylane® Defyne

-Summary

To determine if subjects who receive premaxillary injection demonstrate an increase in nasal tip projection and an associated increase in upper lip projection, and vermillion height.

Expand all sections  ·  Collapse all

+Arms and interventions

ArmTypeInterventionsDescription
Nasal Tip ProjectionExperimentalDevice: Restylane® Defyne
Upper Lip PositionExperimentalDevice: Restylane® Defyne
  • Restylane® Defyne (Device): hyaluronic acid filler injection

+Outcome measures

Primary outcomes

  • Nasal Tip Projection [Baseline and 2 months]: Baseline nasal projection measurements will be documented according to Goode's ratio. The Goode ratio was used as a measurement of tip projection and is defined as the ratio of the nasal height in relation to the nasal length. For each subject's right lateral view photograph, the nasal height was measured as the length of a line drawn from the alar-facial groove to the tip-defining point, and the nasal length was measured as the length of the line drawn from the nasion to the tip-defining point. The nasal height value was then divided by the nasal length value to determine the Goode ratio for a given photograph. The ratio of the line from the alar crease to the nasal tip to the nasion to the nasal tip should be . 55. If it is more than that the nose is overprojected, if it is under that ratio the nose is underprojected.
  • Upper Lip Projection [Baseline and 2 months]: baseline upper lip position will recorded by measuring the Z-angle, which is the intersection of the Frankfort horizontal line and the profile line as described by Merrifield. From the straight portrait image, the ratio of the upper lip vermillion height to the lower lip vermillion height will be documented. Upper lip projection was assessed via measurement of the Z angle. On each subject's right lateral view photograph, a profile line was drawn tangential to the pogonion of the chin and to the most anterior point of the upper lip. A second line was drawn along the Frankfort horizontal plane. The resulting angle at which these two lines intersected corresponded to the Z angle. A decrease in the Z angle to a more acute value on post-treatment photographs would correspond to an increase in upper lip projection.

+Eligibility

Sex: All, ages: 21 Years to 70 Years, accepts healthy volunteers

Inclusion Criteria:

* 1\. Subjects Age 21 to 70. 2. Subjects who demonstrate signs of perioral aging or poor upper lip projection.

Exclusion Criteria:

* 1\. Subjects who plan to undergo peri oral neurotoxin treatments or ablative skin treatments, or have had either of these treatments in the previous 6 months, other injectable filler treatments during the course of the study.

  2\. Subjects who are pregnant or nursing. 3. Subjects with a known allergy or sensitivity to any component of the study ingredients.

  4\. Any history of rhinoplasty or nasal filler injections. 5. Recent history of upper lip augmentation (surgical and non-surgical) within the last 12 months.

  6\. Any history of lip lift or other surgical procedures involving the upper lip.

  7\. Any history of chin augmentation (surgical and non-surgical). 8. Any history of orthognathic surgery. 9. Any history of bleeding disorders (iatrogenic or otherwise). 10. Current history of chronic drug or alcohol abuse. 11. Concurrent therapy that, in the investigator's opinion, would interfere with the evaluation of the safety or efficacy of the study product (i.e. immunosuppressive therapy).

  12\. Subjects who, in the Investigator's opinion, have a history of poor cooperation, non¬compliance with medical treatment or unreliability.

+Posted results

Participant flow

MilestoneNasal Tip ProjectionUpper Lip Position
Started1010
Completed1010
Not completed00

Outcome results

  • Nasal Tip Projection (Primary), Mean, ratio: Nasal Tip Projection 0.601 +/- 0.052
  • Upper Lip Projection (Primary), Mean, degrees: Upper Lip Position 74.245 +/- 10.859

Adverse events

Time frame: 2 months

ArmDeathsSerious adverse eventsOther adverse events
Nasal Tip Projection0/10 (0.0%)0/10 (0.0%)0/10 (0.0%)
Upper Lip Position0/10 (0.0%)0/10 (0.0%)0/10 (0.0%)

+Locations (1)

FacilityCityCountryStatus
DeNova ResearchChicago, IllinoisUnited States

+Study documents

+Investigators

My Notes